BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 15485316)

  • 1. Adjuvant therapy for malignant melanoma.
    Stoutenburg JP; Schrope B; Kaufman HL
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):823-35. PubMed ID: 15485316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?
    Schuchter LM
    J Clin Oncol; 2004 Jan; 22(1):7-10. PubMed ID: 14665612
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant therapy for melanoma.
    Sondak VK
    Cancer J; 2001; 7 Suppl 1():S24-7. PubMed ID: 11504282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b.
    Moschos SJ; Kirkwood JM; Konstantinopoulos PA
    J Clin Oncol; 2004 Jan; 22(1):11-4. PubMed ID: 14665613
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapy for cutaneous melanoma.
    Treisman J; Garlie N
    Clin Plast Surg; 2010 Jan; 37(1):127-46. PubMed ID: 19914464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant high-dose interferon-alpha therapy for high-risk melanoma.
    Kirkwood JM; Tarhini AA
    Forum (Genova); 2003; 13(2):127-40; quiz 187-8. PubMed ID: 14732880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current management of melanoma: benefits of surgical staging and adjuvant therapy.
    McMasters KM; Swetter SM
    J Surg Oncol; 2003 Mar; 82(3):209-16. PubMed ID: 12619066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting.
    Garbe C; Hauschild A; Volkenandt M; Schadendorf D; Stolz W; Reinhold U; Kortmann RD; Kettelhack C; Frerich B; Keilholz U; Dummer R; Sebastian G; Tilgen W; Schuler G; Mackensen A; Kaufmann R
    Melanoma Res; 2008 Apr; 18(2):152-60. PubMed ID: 18337653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.
    Spitler LE; Weber RW; Allen RE; Meyer J; Cruickshank S; Garbe E; Lin HY; Soong SJ
    J Immunother; 2009; 32(6):632-7. PubMed ID: 19483646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant therapy of malignant melanoma.
    Dickler MN; Coit DG; Meyers ML
    Surg Oncol Clin N Am; 1997 Oct; 6(4):793-812. PubMed ID: 9309094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous head and neck melanoma: the old and the new.
    Rigual NR; Popat SR; Jayaprakash V; Jaggernauth W; Wong M
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):403-12. PubMed ID: 18366288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current therapy of cutaneous melanoma.
    Mays SR; Nelson BR
    Cutis; 1999 May; 63(5):293-8. PubMed ID: 10349545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.
    Kalani AD; Jack A; Montenegro G; Degliuomini J; Wallack MK
    G Ital Dermatol Venereol; 2008 Feb; 143(1):59-70. PubMed ID: 18833052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III adjuvant studies in operable malignant melanoma (review).
    Lejeune FJ
    Anticancer Res; 1987; 7(4B):701-5. PubMed ID: 3314671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations.
    Kirkwood JM; Moschos S; Wang W
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2331s-2336s. PubMed ID: 16609054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adjuvant interferon treatment of melanoma].
    Török L
    Magy Onkol; 2003; 47(1):105-7. PubMed ID: 12704462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidisciplinary treatment of primary melanoma.
    Yao K; Balch G; Winchester DJ
    Surg Clin North Am; 2009 Feb; 89(1):267-81, xi. PubMed ID: 19186240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant interferon therapy for melanoma.
    Hancock B; Wheatley K; Ives N; Gore M
    J Clin Oncol; 2005 Apr; 23(10):2431; author reply 2431-2. PubMed ID: 15800339
    [No Abstract]   [Full Text] [Related]  

  • 20. Correspondence re: G. C. de Gast et al., Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin. Cancer Res., 6: 1267-1272, 2000.
    Meyers FJ; O' Donnell RT
    Clin Cancer Res; 2000 Oct; 6(10):4167. PubMed ID: 11051273
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 34.